Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rx Or OTC Statins May Be Springboard For Perrigo Generics Unit

This article was originally published in The Tan Sheet

Executive Summary

Perrigo is looking into developing its own line of private label statin drugs

You may also be interested in...



Perrigo To Develop New Products With Bentley

Bentley's development and distribution deal with Perrigo for new formulations of current products gives the company a solid foray into the U.S. specialty pharmaceuticals market with a proven sales force

Perrigo To Develop New Products With Bentley

Bentley's development and distribution deal with Perrigo for new formulations of current products gives the company a solid foray into the U.S. specialty pharmaceuticals market with a proven sales force

Perrigo To Develop New Products With Bentley

Bentley's development and distribution deal with Perrigo for new formulations of current products gives the company a solid foray into the U.S. specialty pharmaceuticals market with a proven sales force

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS097468

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel